Searched for
NORVASC
Unichem gets USFDA nod for generic hypertension tabletsUnichem Laboratories today said it has received approval from the US health regulator USFDA for its generic amlodipine besylate tablets use...- Cipla in talks to supply drugs to Germany’s BIBoehringer Ingelheim in talks with Cipla for supply of generic drugs to the $17-bn German coa for two drugs.
- Glaxo, Pfizer’s patent claims turned downIndian authorities have rejected the patent applications of GlaxoSmithkline’s anti-diabetic drug Avandia and Pfizer’s cholesterol lowering ...
- Pfizer, Aurobindo ink marketing dealPFIZER has entered into a series of agreements with Aurobindo Pharma to market medicines that are no longer patent protected and don’t have...
- Ranbaxy, Pfizer sign truce over LipitorRanbaxy has settled most of its patent disputes with Pfizer, allowing it to launch a generic version of Lipitor from November 30, 2011. Ran...
- Pfizer again sues Ranbaxy over LipitorPfizer has filed two separate patent infringement cases against Ranbaxy in a bid to extend the exclusivity of its $13-billion anti-choleste...
- Boutique products set to move ahead of topselling drugsThere is no quick remedy for what ails the pharmaceutical industry: a tougher environment for drug approvals and a dwindling pipeline of ne...
- Bristol-Myers to shut half of its plants in 3 yearsApart from plant shutdowns, the company plans to lay off about 4,300 employees in a broad restructuring aimed at cost savings of $1.5 b by ...
- Wockhardt gets FDA nod to enter US Norvasc marketWockhardt has launched Amlodipine tablets in US market. The tablets are in strengths of 2.5 mg, 5 mg and 10 mg. The US market for Amlodipin...
- Lupin gets US nod for hypertension drugThe company's Amlodipine Besylate tablets are AB-rated generic equivalent of Pfizer's Norvasc tablets.
- Ranbaxy gets tentative US nod for TamsulosinRanbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories, has received tentative approval from the U.S. Food a...
- Mylan buys Merck’s generics unitMylan Laboratories agreed to buy Merck KGaA’s generic-drug unit for 4.9 billion euros ($6.7 billion) in cash to become the world’s third-la...
- Local generic cos eye US windfallIndian generic pharma companies may now find it easier to challenge patents in the US. In another twist in the battle between innovators an...
- Ranbaxy to challenge Pfizer’s suit on CaduetRanbaxy has said the company will challenge the litigation filed by Pfizer, the world’s largest drug maker.
Load More- Pfizer, Aurobindo ink marketing deal
